Skip to the beginning of the images gallery

Retifanlimab (anti-PD-1) - Primary antibody, specific to PDCD1, >95%, high purity, Human IgG4SP, Antibody of programmed cell death 1 (CD279)

≥95%(SDS-PAGE&SEC)
Lot by Lot

Application:

Animal Model
ELISA
Flow Cytometry
Functional Assay

Features and benefits

Host species: Human
Species reactivity(Reacts with): Cynomolgus monkey,Human
Isotype: Human IgG4SP
Conjugation: Unconjugated

Item Number

Ab175644

Grouped product items
SKU	Size	Availability	Price
Ab175644-100μg	100μg	In stock	$59.90
Ab175644-1mg	1mg	In stock	$279.90
Ab175644-5mg	5mg	In stock	$739.90
Ab175644-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,189.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series

Click to view target information: PDCD1

Accession#:Q15116 Gene ID:5133 PD1 PDCD1 programmed cell death 1 (CD279) Antibody

Basic Description

Product Name	Retifanlimab (anti-PD-1) - Primary antibody, specific to PDCD1, >95%, high purity, Human IgG4SP
Synonyms	CD279 antibody \| CD279 antigen antibody \| hPD 1 antibody \| hPD l antibody \| hPD-1 antibody \| hSLE1 antibody \| PD 1 antibody \| PD-1 antibody \| PD1 antibody \| PDCD 1 antibody \| PDCD1 antibody \| PDCD1_HUMAN antibody \| Programmed cell death 1 antibody \| Progr
Specifications & Purity	ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Host species	Human
Specificity	PDCD1
Conjugation	Unconjugated
Grade	Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type	ANTAGONIST
Mechanism of action	Antibody of programmed cell death 1 (CD279)
Product Description	Retifanlimab (anti-PD-1) is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab (anti-PD-1) can be used for the research of gastroesophageal adenocarcinoma (GEA).

Product Properties

Isotype	Human IgG4SP
Light Chain Type	kappa
SDS-PAGE	25.5 kDa (Light Chain) & 50.1kDa (Heavy Chain), under reducing conditions; 179.1 kDa, under non-reducing conditions.
Purification Method	Protein A purified
Purity	>95%
Form	Liquid
Concentration	Lot by Lot
Storage Temp	Store at -80°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS	2079108-44-2

Images

Retifanlimab (anti-PD-1) (Ab175644) - Flow Cytometry
Flow Cytometry analysis of 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated MOLT-4 cells (24h) labelling PD-1 (red) with Retifanlimab (anti-PD-1) (Ab175644). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Retifanlimab (anti-PD-1) (Ab175644) - ELISA
Immobilized hu-PD-1 at 2 μg/mL can bind Retifanlimab (anti-PD-1) (Ab175644) with the EC₅₀ of 55.56 ng/mL.

Retifanlimab (anti-PD-1) (Ab175644) - SEC
The purity of Retifanlimab (anti-PD-1) (Ab175644) is more than 95% verified by HPLC.

Retifanlimab (anti-PD-1) (Ab175644) - ELISA
Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Retifanlimab (anti-PD-1) (Ab175644) with the EC50 of 11.39 ng/mL.

Associated Targets(Human)

PDCD1 Tclin Programmed cell death protein 1 (0 Activities)

Discover Target: PDCD1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PDCD1 Tclin Programmed cell death protein 1 (14 Activities)

Discover Target: PDCD1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number	Certificate Type	Date	Item
ZJ24F0303705	Certificate of Analysis	Mar 26, 2024	Ab175644
ZJ24F0303704	Certificate of Analysis	Mar 26, 2024	Ab175644
ZJ24F0303703	Certificate of Analysis	Mar 26, 2024	Ab175644

References

1. Farias JPF, Rangel da Silva MHC, Jácome AA. (2021) Emerging and Experimental Agents for Anal Cancer: What is New?. J Exp Pharmacol, 13 (13): (433-440). [PMID:33859504] [10.1021/op500134e]
2. Kline J, Gajewski TF. (2010) Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.. Curr Opin Investig Drugs, 11 (12): (1354-9). [PMID:21154117] [10.1021/op500134e]
3. Hall RD, Gray JE, Chiappori AA. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.. Cancer Control, 20 (1): (22-31). [PMID:23302904] [10.1021/op500134e]
4. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al.. (2017) Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.. Mol Cancer Ther, 16 (5): (861-870). [PMID:28265006] [10.1021/op500134e]
5. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips. (1997-10-23) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.. Gene, 197 ((1-2)): (177-187). [PMID:9332365]
6. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T.. (1994) Structure and chromosomal localization of the human PD-1 gene (PDCD1).. Genomics, [PMID:7851902]
7. Prokunina, Ludmila L and 23 more authors.. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.. Nature genetics, [PMID:12402038]
8. Topalian, Suzanne L SL and 29 more authors.. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.. The New England journal of medicine, (28): [PMID:22658127]
9. Robert, Caroline C and 27 more authors.. (2015) Nivolumab in previously untreated melanoma without BRAF mutation.. The New England journal of medicine, (22): [PMID:25399552]
10. McDermott, J J and Jimeno, A A.. (2015) Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.. Drugs of today (Barcelona, Spain : 1998), [PMID:25685857]
11. Na, Zhenkun and 6 more authors.. (2017) Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.. Cell research, [PMID:27325296]
12. Pascolutti, Roberta R and 6 more authors.. (2016) Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.. Structure (London, England : 1993), (4): [PMID:27618663]
13. Horita, Shoichiro S and 5 more authors.. (2016) High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.. Scientific reports, (13): [PMID:27734966]
14. Tan, Shuguang S and 15 more authors.. (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.. Nature communications, (6): [PMID:28165004]
15. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ.. (2018) PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.. Gene, (5): [PMID:28951311]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.